Error
Sorry, the page you're looking for has moved or doesn't exist.
You can access content using the navigation or using the search function.
Articles and blogs
|
December 07, 2022 · Public Policy & Regulatory Affairs Team
Brief updates on several recent policy developments across the country. Read more... |
|
|
November 16, 2022 · Public Policy & Regulatory Affairs Team
Brief updates on several recent policy developments across the country. Read more... |
|
November 09, 2022 · Public Policy & Regulatory Affairs Team
The Policy Guys can’t match the math skills of Optum’s Carla Gee as she explains how a State Fee Schedule helps to control costs and maintain consistency in medical service reimbursement. Read more... |
|
October 20, 2022 · Clinical Team
When it comes to unused prescription medications, the Drug Enforcement Agency (DEA) encourages everyone to “Keep them safe. Clean them out. Take them back.” They enforce this motto by sponsoring National Prescription Drug Take Back Days. Read more... |
|
September 12, 2022 · Optum Auto No-Fault
While auto and workers’ comp insurers see many of the same kinds of claims, handling auto claims takes a specialized knowledge base to reach the best outcomes for payers and patients Read more... |
|
|
September 07, 2022 · Public Policy & Regulatory Affairs Team
Brief updates on several recent policy developments across the country. Read more... |
|
|
September 01, 2022 · Public Policy & Regulatory Affairs Team
The Policy Guys Read more... |
|
|
August 17, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
|
|
July 28, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
|
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
Page 8 of 11